Published in Surg Clin North Am on February 01, 1978
A framework for a personalized surgical approach to ovarian cancer. Nat Rev Clin Oncol (2015) 1.17
Metastatic disease to the breast: the Washington University experience. World J Surg Oncol (2007) 0.95
Long-term follow-up of patients with advanced ovarian cancer treated in randomised clinical trials. Br J Cancer (1995) 0.94
Phase I clinical and pharmacological study of intraperitoneal cis-bis-neodecanoato( trans- R, R-1, 2-diaminocyclohexane)-platinum II entrapped in multilamellar liposome vesicles. J Cancer Res Clin Oncol (2003) 0.89
Primary metastatic breast cancer: the impact of locoregional therapy. Breast Care (Basel) (2014) 0.88
Statement by the Kommission OVAR of the AGO Study Group on the Use of HIPEC (Hyperthermic Intraperitoneal Chemotherapy) to Treat Primary and Recurrent Ovarian Cancer. Geburtshilfe Frauenheilkd (2013) 0.81
Role of primary surgery in advanced ovarian cancer. World J Surg Oncol (2004) 0.78
Treating ovarian cancer. Br Med J (Clin Res Ed) (1986) 0.78
Evolution of surgery in advanced epithelial ovarian cancer in a dedicated gynaecologic oncology unit-seven year audit from a tertiary care centre in a developing country. Ecancermedicalscience (2014) 0.78
When should surgical cytoreduction in advanced ovarian cancer take place? J Oncol (2009) 0.75
Recent progress in the treatment of epithelial ovarian malignancy. West J Med (1982) 0.75
A radioimmunoassay using a monoclonal antibody to monitor the course of epithelial ovarian cancer. N Engl J Med (1983) 8.82
The mesothelial keratins: a new family of cytoskeletal proteins identified in cultured mesothelial cells and nonkeratinizing epithelia. Cell (1982) 4.17
Surgical resection of tumor bulk in the primary treatment of ovarian carcinoma. Natl Cancer Inst Monogr (1975) 2.75
Clear cell carcinoma of the ovary: a distinct histologic type with poor prognosis and resistance to platinum-based chemotherapy in stage III disease. Gynecol Oncol (1996) 2.21
Stage IB and IIA cervical cancer with negative lymph nodes: the role of adjuvant radiotherapy after radical hysterectomy. Gynecol Oncol (1997) 1.57
Histologic transformation of benign endometriosis to early epithelial ovarian cancer. Gynecol Oncol (1996) 1.54
Role of cytoreductive surgical treatment in the management of advanced ovarian cancer. Cancer Treat Rep (1979) 1.50
Specificity of increased renal clearance of amylase in diagnosis of acute pancreatitis. N Engl J Med (1975) 1.50
Prognostic significance of DNA content in epithelial ovarian cancer. Gynecol Oncol (1994) 1.43
Management of ovarian carcinoma. Current concepts and future prospects (first of two parts). N Engl J Med (1976) 1.43
Prognostic importance of intraoperative rupture of malignant ovarian epithelial neoplasms. Obstet Gynecol (1994) 1.42
Endometrial cancer in women 40 years old or younger. Gynecol Oncol (2001) 1.20
Human ovarian cancer, cell lines, and primary ascites cells express the human Mullerian inhibiting substance (MIS) type II receptor, bind, and are responsive to MIS. Clin Cancer Res (1999) 1.20
Uterine leiomyosarcoma and endometrial stromal sarcoma: lymph node metastases and sites of recurrence. Gynecol Oncol (1993) 1.20
Epithelial ovarian carcinoma in the reproductive age group. Cancer (1999) 1.12
Müllerian inhibiting substance as a marker for ovarian sex-cord tumor. N Engl J Med (1992) 1.11
Clear cell adenocarcinoma of the ovary: a clinical analysis and comparison with serous carcinoma. Gynecol Oncol (1989) 1.11
The clinical utility of liposomal doxorubicin in recurrent ovarian cancer. Gynecol Oncol (2001) 1.10
Ovarian clear cell carcinoma. A clinicopathologic analysis of 44 cases. Int J Gynecol Pathol (1989) 1.10
Central nervous system involvement by ovarian carcinoma: a complication of prolonged survivial with metastatic disease. Cancer (1978) 1.09
Advanced ovarian cancer: primary treatment with surgery, radiotherapy, and chemotherapy. Cancer (1972) 1.05
Characterization of a xenograft model of human ovarian carcinoma which produces intraperitoneal carcinomatosis and metastases in mice. Int J Cancer (1996) 1.05
Combination chemotherapy with adriamycin-cyclophosphamide for advanced ovarian carcinoma. Cancer (1980) 1.00
Preliminary trial of aminoglutethimide in breast cancer. Cancer (1973) 0.99
The effect of postsurgical therapy on stage III endometrial carcinoma. Gynecol Oncol (1996) 0.98
Epithelial ovarian tumors of borderline malignancy: long-term follow-up. Gynecol Oncol (1993) 0.97
Squamous cell carcinoma of the endometrium: a report of eight cases and a review of the literature. Gynecol Oncol (1996) 0.96
Prognostic implication of endometriosis in clear cell carcinoma of the ovary. Gynecol Oncol (2008) 0.96
Stage IE primary malignant lymphomas of the uterine cervix. Cancer (1991) 0.94
Female adnexal tumor of probable Wolffian origin with multiple recurrences over 16 years. Cancer (1985) 0.94
Surgical stage IV endometrial carcinoma: a study of 47 cases. Gynecol Oncol (1994) 0.93
Toxic-shock syndrome. N Engl J Med (1980) 0.92
Patterns of pulmonary metastasis from uterine cancer. Oncology (1996) 0.92
Mucinous adenocarcinomas of the vulva. Gynecol Oncol (1995) 0.91
Management of ovarian carcinoma. Current concepts and future prospects. N Engl J Med (1976) 0.91
Mullerian inhibiting substance reduction of colony growth of human gynecologic cancers in a stem cell assay. Gynecol Oncol (1985) 0.91
Diagnostic utility of Müllerian inhibiting substance determination in patients with primary and recurrent granulosa cell tumors. Gynecol Oncol (1999) 0.91
Radiation therapy in stage II ovarian carcinoma: the influence of histologic grade. Cancer (1980) 0.90
Diagnosis of a supernumerary ovary with human chorionic gonadotropin. Obstet Gynecol (1976) 0.89
Uterine papillary serous carcinoma (UPSC): a clinicopathologic study of 30 cases. Gynecol Oncol (1995) 0.89
Mullerian inhibiting substance inhibits colony growth of a human ovarian carcinoma cell line. J Clin Endocrinol Metab (1982) 0.88
Malignant mixed müllerian tumors of the ovary: experience with surgical cytoreduction and combination chemotherapy. Cancer (1995) 0.87
Borderline tumors of the ovary: correlation of frozen and permanent histopathologic diagnosis. Obstet Gynecol (2000) 0.87
Natural history of patients with pulmonary metastases from uterine cancer. Cancer (1996) 0.87
Laparoscopy for second-look evaluation in ovarian cancer. Obstet Gynecol (1981) 0.85
Primary treatment of Bartholin's gland carcinoma with radiation and chemoradiation: a report on ten consecutive cases. Int J Gynecol Cancer (2007) 0.85
Intraoperative radiation therapy in the treatment of pelvic gynecologic malignancies: a review of fifteen cases. Gynecol Oncol (2000) 0.84
Quality of life in advanced ovarian cancer: identifying specific concerns. J Palliat Med (1999) 0.84
Cancer chemotherapy following adrenalectomy in breast cancer patients. Cancer (1969) 0.83
Predictive factors for long-term survival in patients with advanced ovarian cancer. Gynecol Oncol (1989) 0.83
Mullerian inhibiting substance inhibits growth of a human ovarian cancer in nude mice. Ann Surg (1981) 0.83
Phase I/II dose finding study of combination cisplatin and gemcitabine in patients with recurrent cervix cancer. Gynecol Oncol (2006) 0.82
Pulmonary resection for metastases from gynecologic cancers: Massachusetts General Hospital experience, 1943-1982. Gynecol Oncol (1985) 0.82
Lymph node metastases from carcinoma of the cervix, stages IB and IIA: implications for prognosis and treatment. Gynecol Oncol (1982) 0.82
Fallopian tube prolapse after hysterectomy. A report of two cases. J Reprod Med (1988) 0.82
Predictors of recurrence in surgical stage II endometrial adenocarcinoma. Gynecol Oncol (1999) 0.81
Intraperitoneal immunotherapy of human ovarian carcinoma with Corynebacterium parvum. Cancer Res (1983) 0.80
Use of progestational agents in the management of endometrial cancer. Cancer (1965) 0.80
Carcinosarcomas and mixed Müllerian tumors of the fallopian tube. Gynecol Oncol (1989) 0.80
Primary leiomyosarcoma of the fallopian tube. Gynecol Oncol (1993) 0.79
Ultrasound-guided intrauterine removal of intrauterine contraceptive devices in pregnancy. Obstet Gynecol (1988) 0.79
Müllerian inhibiting substance: gene structure and mechanism of action of a fetal regressor. Recent Prog Horm Res (1987) 0.79
Recurrent psammocarcinoma of the peritoneum with complete response to tamoxifen therapy. Gynecol Oncol (1998) 0.78
High-dose methotrexate with leucovorin rescue in ovarian cancer: a phase II study. Cancer Treat Rep (1979) 0.78
Recurrent ovarian granulosa cell tumor: role of combination chemotherapy with report of a long-term response to a cyclophosphamide, doxorubicin and cisplatin regimen. Eur J Gynaecol Oncol (1990) 0.78
Combination chemotherapy in advanced adenocarcinoma of the fallopian tube. Gynecol Oncol (1991) 0.78
Clear cell adenocarcinoma of the vagina: a second primary in a diethylstilbestrol-exposed woman? Gynecol Oncol (1991) 0.78
Prognostic variables in the treatment of squamous cell carcinoma of the vulva. Gynecol Oncol (1986) 0.77
Hypocalcemia--an unusual metabolic complication of breast cancer. N Engl J Med (1966) 0.77
Müllerian inhibiting substance inhibition of a human endometrial carcinoma cell line xenografted in nude mice. Gynecol Oncol (1984) 0.77
A Phase I study of continuous infusion doxorubicin and paclitaxel chemotherapy with granulocyte colony-stimulating factor for relapsed epithelial ovarian cancer. Clin Cancer Res (1999) 0.77
The clinical diagnosis of early cervical cancer. Obstet Gynecol Surv (1969) 0.76
A Phase I-II study of 96-hour infusional topotecan and paclitaxel for patients with recurrent Müllerian tumors. Cancer (2001) 0.76
Nodal metastasis is highly consistent in squamous cell carcinoma of the vulva. J Clin Oncol (2001) 0.75
The fluorescent cytoprint assay in gynecological malignancies and breast cancer. Methodology and results. Contrib Gynecol Obstet (1994) 0.75
A phase I clinical trial of continual alternating etoposide and topotecan in refractory solid tumours. Br J Cancer (2005) 0.75
Nodal metastasis is highly consistent in squamous cell carcinoma of the vulva. J Clin Oncol (2001) 0.75
Elevated CA 125 serum levels and epithelial ovarian cancer metastatic to retroperitoneal lymph nodes. Gynecol Oncol (1988) 0.75
The DES syndrome and clear cell adenocarcinoma in young women. Cancer Nurs (1978) 0.75
Ovarian cancer cachexia--surgical interactions. Gynecol Oncol (1979) 0.75
Sarcomas of the uterine corpus: prognostic factors and treatment. Radiother Oncol (1984) 0.75
Intraperitoneal immunotherapy of epithelial ovarian carcinoma with Corynebacterium parvum. Am J Obstet Gynecol (1985) 0.75
Trends in drug orientations and behavior: changes in a rural community, 1975-1982. Int J Addict (1985) 0.75
Effect of castration, estrogen, and timed progestins on induced endometrial carcinoma in the rabbit. Gynecol Oncol (1975) 0.75
Low-dose preoperative radiation therapy for adenocarcinoma of the endometrium. A pilot study. Cancer (1984) 0.75
cis-Diamminedichloroplatinum(II) therapy for advanced ovarian cancer. Cancer Treat Rep (1981) 0.75
Youth at risk: marijuana use among Native American and Caucasian youths. Int J Addict (1983) 0.75
Clinical update: toxic shock syndrome. J Emerg Nurs (1982) 0.75
Role of the primary physician in the detection and treatment of gynecologic cancer. Prim Care (1981) 0.75
Occult pleural involvement in stage III ovarian carcinoma: role of diaphragm resection. Gynecol Oncol (1990) 0.75
Successful long-term palliation of stage IV vulvar carcinoma with operation and bleomycin sulfate. Am J Obstet Gynecol (1978) 0.75
Primary mucinous carcinoid tumor of the ovary. A case report. Int J Gynecol Pathol (1989) 0.75
Primary adenocarcinoma of the fallopian tube. Eur J Gynaecol Oncol (1989) 0.75
Postoperative management of patients with stage Ib endometrial carcinoma. Eur J Gynaecol Oncol (1996) 0.75
Immunity, trophoblast, and trophoblastic neoplasia. Clin Obstet Gynecol (1977) 0.75
Malignant hemangioendothelioma of the uterus. Gynecol Oncol (1979) 0.75
Management of high-grade stage I adenocarcinoma of the endometrium: hysterectomy following low dose external beam pelvic irradiation. Gynecol Oncol (1986) 0.75
Toxic shock syndrome occurring in the luteal phase of the menstrual cycle. Am J Obstet Gynecol (1981) 0.75
Use of progestational agents in the management of metastatic carcinoma of the endometrium. Clin Obstet Gynecol (1968) 0.75